Insider buying last 90 days
No open-market insider purchases were filed for TSHA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TSHA insider filing, plotted on the chart in Gekko.Open TSHA in Gekko
NASDAQ: TSHA
Taysha Gene Therapies (TSHA) Stock Analysis & Forecast
Oct 12 close
$4.14−0.35 (−7.8%)
Gekko Brief
Oct 12 closeTaysha Gene Therapies closed at $4.14 on 12 October 2026, -7.8% on the day. The price sits between the 50-day ($5.47) and 200-day ($5.42) moving averages, inside a 52-week range of $3.69 to $7.30. The GekkoIndex reads 73.2, in the Buying zone, up 2 points over five sessions. Gekko Fair Value is $7.20, so the price is 42.5% below it.
The next earnings report is due on 3 November 2026, 22 days away (before open). Over the last 8 reports the company beat the earnings estimate 3 times, with an average move of 6.3% across the report. Seasonally, the next 20 trading days from this point averaged -12.7% over the last 5 years, rising in 1 of them.
8 firms rate the stock: 8 buy, 0 hold and 0 sell, with a consensus target of $13.00. A typical daily move is about 6.3%, and a typical 20-day move about 15.5%. On the swing-trade checklist, 2 items read supportive and 2 read as a headwind (earnings risk, seasonality).
A plain summary of the figures as of the Oct 12, 2026 close.
Taysha Gene Therapies price vs fair value
Close $4.14200-day averageGekko Fair Value $7.20
Taysha Gene Therapies quick facts
- Market cap
- $1.32B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.41
- Revenue, TTM
- $5.49M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.17
- Volume
- 2.24M avg 3.88M
- 1-year return
- −17.2%
- Typical daily move
- ±6.3%
- Typical 20-day move
- ±15.5%
- 50-day average
- $5.47
- 200-day average
- $5.42
- Next earnings
- Nov 3 before open
- Shares outstanding
- 325.8M
Taysha Gene Therapies swing-trade checklist
Taysha Gene Therapies scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $4.14 sits between the 50-day ($5.47) and 200-day ($5.42) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
73.2, Buying
Reading 73.2 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
42.5% below
Price is 42.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−12.7% on average
From this point in the calendar, the next 20 trading days averaged −12.7% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Taysha Gene Therapies stock chart and price history
Taysha Gene Therapies closed at $4.14 on Oct 12, 2026, −17.2% over the past year, inside a 52-week range of $3.69 to $7.30.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −17.5%
- 3 months
- −27.4%
- 6 months
- −6.3%
- 1 year
- −17.2%
The full TSHA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TSHA in Gekko
Follow Taysha Gene Therapies through every session
Put TSHA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TSHA in GekkoFree for 7 days. No credit card required.
About Taysha Gene Therapies
Taysha Gene Therapies develops gene therapies built on adeno-associated virus vectors, with its work centered on inherited conditions that affect the central nervous system. The company is best known for a pipeline of AAV-based treatments aimed at rare genetic disorders, including programs targeting giant axonal neuropathy, Rett syndrome, CLN1 disease, SLC13A5 deficiency, and GM2 gangliosidosis.
Its pipeline spans multiple candidate therapies at different stages, each matched to a specific inherited CNS disease. Taysha works alongside The University of Texas Southwestern Medical Center as a partner in developing and bringing these gene therapy programs toward the market, combining its own research efforts with that collaboration.
Taysha Gene Therapies was founded in 2019 and is headquartered in Dallas, Texas. Its shares are listed on the NASDAQ under the ticker TSHA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- tayshagtx.com
Taysha Gene Therapies GekkoIndex: the smart money zone
Taysha Gene Therapies’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 73.2, in the Buying zone, up 2 points over five sessions.
73.2Buying
Up 2 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 24 | +9.5% | +54.2% | ||
| Accumulation | 263 | +1.8% | +12.4% | ||
| Neutral | 352 | +1.4% | +2.6% | ||
| Distribution | 38 | −0.9% | −7.2% | ||
| Selling | 5 | Too few readings yet | |||
Average TSHA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the TSHA price, zone by zone.Track TSHA in Gekko
Is Taysha Gene Therapies stock overvalued? Gekko Fair Value
Taysha Gene Therapies trades 42.5% below Gekko Fair Value of $7.20, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Taysha Gene Therapies shares are worth, recalculated every trading day.
$7.20
Gekko Fair Value, Oct 10, 2026
42.5% Undervalued
At the end of Aug 2026 the price was 47.4% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open TSHA in Gekko
Taysha Gene Therapies insider and Congress trading
No open-market insider purchases were filed for Taysha Gene Therapies, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TSHA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TSHA, plotted on the chart in Gekko.Open TSHA in Gekko
Buybacks
Taysha Gene Therapies has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2025
- $173K
- As a share of market cap
- 0.01%
From company filings.
Taysha Gene Therapies earnings: next date and track record
Taysha Gene Therapies reports on Nov 3, 2026, before the open (22 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected before the open, 22 days away
- EPS estimate
- −$0.13
- Revenue estimate
- $756K
3 of 8reports beat the EPS estimate
±6.3%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 11, 2026 AI summary
- What they said
- Taysha Gene Therapies reported a productive Q2 2026 focused on advancing its lead gene therapy candidate TSHA-102 toward potential regulatory approval. Management highlighted completion of dosing in the REVEAL pivotal and ASPIRE trials, presentation of encouraging longer-term Part A REVEAL data showing deepening and durable multi-domain functional gains (including a 100% responder rate at 12 months in 12 patients), expanded manufacturing partnership with Catalent, payer research to inform reimbursement planning, and a successful follow-on financing (gross proceeds $230M) that leaves cash and equivalents of $455.4M. The company expects its cash runway to support operations into H2 2028 and continues CMC and BLA-enabling activities, with completion of the PPQ campaign expected in Q4 2026 and top-line 6-month interim REVEAL data and FDA feedback on the BLA pathway anticipated in H1 2027. The call addressed a Grade 2 SAE (sensory peripheral neuropathy) in one patient, characterized as an expected AAV9-associated event, managed through immunomodulatory therapy and disclosed to FDA and IDMC (no follow-up concerns). Management reiterated confidence in safety management, durability of response, and commercial readiness work while noting continued regulatory engagement and additional data-readout and CMC milestones ahead.
- Guidance
- - Expected completion of BLA-enabling PPQ campaign in Q4 2026. - Anticipated reporting of topline 6-month interim analysis of the REVEAL pivotal trial and FDA feedback on the BLA submission pathway in H1 2027. - Management expects current cash resources (~$455.4M as of June 30, 2026) to support planned operating expenses and capital requirements into the second half of 2028. - Continued commercial readiness activities (payer research, manufacturing partnership) ongoing; further commercial organization details to be provided later.
- Risks flagged
- - Safety risk: A Grade 2 sensory peripheral neuropathy event reported; AAV9-associated peripheral neuropathies are a known risk and Rett patients have baseline neuropathy risk. - Regulatory risk: BLA pathway depends on ongoing FDA engagement and analytical comparability following PPQ completion. - CMC/manufacturing risk: PPQ completion, comparability and remaining validations are critical path activities that could affect timing. - Clinical risk: Small sample sizes in Part A and trial variability; potential for adverse events or different outcomes in larger populations. - Commercial/reimbursement risk: Payer acceptance, pricing/reimbursement strategy for a one-time intrathecal gene therapy remains uncertain and may affect uptake. - Financial risk: Continued net losses and reliance on follow-on financing or milestones if unexpected delays occur (though current runway is into H2 2028).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 11, 2026 | −$0.13 est −$0.11 | — est $680K | +0.6% |
| May 6, 2026 | −$0.11 est −$0.10 | — est $756K | −3.9% |
| Mar 19, 2026 | −$0.07 est −$0.10 | $5.48M est $2.24M | −1.1% |
| Nov 4, 2025 | −$0.09 est −$0.09 | — est $1.89M | −9.6% |
| Aug 12, 2025 | −$0.09 est −$0.07 | $1.99M est $1.73M | +9.8% |
| May 15, 2025 | −$0.08 est −$0.08 | $2.30M est $1.08M | +13.9% |
| Feb 26, 2025 | −$0.07 est −$0.08 | $2.02M est $2.05M | −6.5% |
| Nov 13, 2024 | −$0.07 est −$0.09 | $1.79M est $2.05M | −5.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Taysha Gene Therapies stock forecast and analyst price targets
Analysts’ average 12-month price target for Taysha Gene Therapies is $13.00, +214.0% from the last close, from 8 firms rating the stock in the last 90 days.
$13.00consensus 12-month target, +214.0% from the last close
Now $4.14Avg $13.00
Low $11High $19
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 17 | Wolfe Research | — | — |
| Aug 14 | Bank of America Securities | — | — |
| Aug 12 | Piper Sandler | $12 | +189.9% |
| Aug 12 | Wells Fargo | $11 | +165.7% |
| Aug 12 | Needham | $12 | +189.9% |
+54.2%average 20-day move after past Buying readings
−12.7%average move over the next 20 trading days in the last 5 years
±6.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Taysha Gene Therapies seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Taysha Gene Therapies averaged −12.7% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −6.2% | 1 of 5 |
| Next 10 trading days | −8.9% | 0 of 5 |
| Next 15 trading days | −5.5% | 1 of 5 |
| Next 20 trading days | −12.7% | 1 of 5 |
| Next 30 trading days | −11.6% | 2 of 5 |
For scale, TSHA’s typical 20-trading-day move in either direction is about 15.5%.
Taysha Gene Therapies market cap and key statistics
Taysha Gene Therapies’s market cap is $1.32B and revenue of $5.49M over the last twelve months.
Valuation
- Market cap
- $1.32B
- EPS, TTM
- −$0.41
- Gekko Fair Value
- $7.20
Trading
- Volume
- 2.24M
- Avg volume, 20 days
- 3.88M
- 52-week high
- $7.30
- 52-week low
- $3.69
- Shares outstanding
- 325.8M
Financials
- Revenue, TTM
- $5.49M
- Profit margin
- 0%
- Return on equity
- -47.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.17
- Typical daily move
- ±6.3%
- Typical 20-day move
- ±15.5%
Taysha Gene Therapies stock news this week
1 headline about Taysha Gene Therapies from the past week, newest first, each linking to the publisher.
Taysha Gene Therapies peers
Taysha Gene Therapies’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Taysha Gene Therapies stock FAQ
What is Taysha Gene Therapies’s market cap?
Taysha Gene Therapies’s market cap is $1.32B at the Oct 12, 2026 close of $4.14, with 325.8M shares outstanding.
What is the Taysha Gene Therapies stock forecast?
The consensus analyst 12-month price target for Taysha Gene Therapies is $13.00, +214.0% from the last close. Of the 8 firms that rated the stock in the last 90 days, 8 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Taysha Gene Therapies stock overvalued or undervalued?
On Gekko’s estimate Taysha Gene Therapies is undervalued: the Oct 12, 2026 close of $4.14 is 42.5% below Gekko Fair Value of $7.20. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Taysha Gene Therapies report earnings next?
Taysha Gene Therapies is expected to report on Nov 3, 2026, before the market opens (22 days away). Analysts expect earnings of −$0.13 per share on revenue of $756K. Taysha Gene Therapies beat the earnings estimate in 3 of its last 8 reports, moving 6.3% on average across the report.
What is Taysha Gene Therapies’s 52-week high and low?
Taysha Gene Therapies’s 52-week high is $7.30 and its 52-week low is $3.69; it closed at $4.14 on Oct 12, 2026, −17.2% over the past year. Over the last five years the shares peaked at $19.11 on Oct 13, 2021.
Is Taysha Gene Therapies stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Taysha Gene Therapies the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.